SILVERARC CAPITAL MANAGEMENT, LLC
Long book
$848.6M
Q1 2026
Positions
67
Top-10 weight
49%
concentration
Last quarter
+21.1%
SPY +14.8%
Turnover
46%
of book per quarter
Strategy in plain words
auto-generated from filingsSILVERARC CAPITAL MANAGEMENT, LLC is a diversified fundamental manager, specialised in healthcare (98% of the long book), running a $848.6M US long book across 67 positions.
The portfolio is moderately concentrated (top 10 ≈ 49% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: KALVISTA PHARMACEUTICALS INC, DIANTHUS THERAPEUTICS INC, COGENT BIOSCIENCES INC, CELCUITY INC, IMMUNOME INC.
Over the last 9 quarters its long book ran on average 0pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-22.1%
Q2 2024
+7.8%
Q3 2024
-11.9%
Q4 2024
-24.1%
Q1 2025
+7.7%
Q2 2025
+33.4%
Q3 2025
+24.0%
Q4 2025
+5.0%
Q1 2026
+21.1%
Sector allocation
Healthcare 90%
Other 8%
Financials 2%
Materials 1%
Long book by quarter
What does SILVERARC CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 2.9M | $57.9M | 6.8% | +18.5% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 654.7K | $54.9M | 6.5% | -12.7% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 1.3M | $50.6M | 6.0% | +5.5% |
| CELC CELCUITY INC | Healthcare | 357.9K | $40.9M | 4.8% | -4.6% |
| IMNM IMMUNOME INC | Healthcare | 1.9M | $40.5M | 4.8% | +64.3% |
| KOD KODIAK SCIENCES INC | Healthcare | 991.9K | $37.8M | 4.5% | -3.0% |
| NUVL NUVALENT INC-A | Healthcare | 354.9K | $36.4M | 4.3% | +14.0% |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 2.0M | $32.9M | 3.9% | +94.5% |
| ERAS ERASCA INC | Healthcare | 1.9M | $30.0M | 3.5% | +40.5% |
| URGN UROGEN PHARMA LTD | Healthcare | 1.5M | $27.0M | 3.2% | -13.6% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 306.0K | $26.6M | 3.1% | +125.1% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 71.6K | $23.1M | 2.7% | -13.2% |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 1.1M | $22.2M | 2.6% | New |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 889.0K | $20.8M | 2.4% | +38.3% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 339.6K | $16.7M | 2.0% | New |
| ALKS ALKERMES PLC | Healthcare | 460.3K | $16.3M | 1.9% | New |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.1M | $13.9M | 1.6% | -1.5% |
| IRON DISC MEDICINE INC | Healthcare | 196.0K | $12.5M | 1.5% | New |
| HLXC HELIX ACQUISITION CORP-CL A | Financials | 1.2M | $12.3M | 1.4% | New |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 197.8K | $11.5M | 1.4% | New |
| CGON CG ONCOLOGY INC | Healthcare | 166.3K | $11.3M | 1.3% | -53.9% |
| IMVT IMMUNOVANT INC | Healthcare | 414.2K | $10.3M | 1.2% | New |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 186.6K | $9.4M | 1.1% | -0.6% |
| BIIB BIOGEN INC | Healthcare | 51.0K | $9.3M | 1.1% | -32.4% |
| GH GUARDANT HEALTH INC | Healthcare | 98.5K | $9.1M | 1.1% | +7.2% |
| PCVX VAXCYTE INC | Healthcare | 145.0K | $8.4M | 1.0% | -2.6% |
| SVRA SAVARA INC | Healthcare | 1.4M | $7.8M | 0.9% | New |
| BNTC BENITEC BIOPHARMA INC | Healthcare | 717.7K | $7.6M | 0.9% | -1.9% |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 150.9K | $7.4M | 0.9% | New |
| CGEN COMPUGEN LTD | Healthcare | 3.3M | $7.1M | 0.8% | -4.7% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 511.1K | $6.1M | 0.7% | -5.6% |
| INSM INSMED INC | Healthcare | 35.9K | $5.9M | 0.7% | -49.7% |
| VCYT VERACYTE INC | Healthcare | 179.7K | $5.8M | 0.7% | -49.7% |
| CERS CERUS CORP | Healthcare | 3.2M | $5.8M | 0.7% | +12.9% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 178.4K | $5.7M | 0.7% | -6.6% |
| CCCC C4 THERAPEUTICS INC | Healthcare | 1.9M | $5.0M | 0.6% | -4.1% |
| CYTK CYTOKINETICS INC | Healthcare | 71.2K | $4.7M | 0.6% | New |
| CLYM CLIMB BIO INC | Healthcare | 684.9K | $4.7M | 0.6% | New |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 859.0K | $4.5M | 0.5% | -18.3% |
| SRZN SURROZEN INC | Healthcare | 144.3K | $4.2M | 0.5% | -8.3% |
| CTNM CONTINEUM THERAPEUTICS INC-A | Healthcare | 301.7K | $3.9M | 0.5% | -1.9% |
| ZURA ZURA BIO LTD | Healthcare | 560.7K | $3.3M | 0.4% | New |
| FULC FULCRUM THERAPEUTICS INC | Healthcare | 419.9K | $3.2M | 0.4% | +6.4% |
| ABEO ABEONA THERAPEUTICS INC | Healthcare | 648.9K | $2.9M | 0.3% | +3.4% |
| CAMP CAMP4 THERAPEUTICS CORP | Healthcare | 653.6K | $2.9M | 0.3% | New |
| ANNX ANNEXON INC | Healthcare | 496.5K | $2.8M | 0.3% | New |
| ELUT ELUTIA INC | Healthcare | 2.5M | $2.6M | 0.3% | -9.2% |
| CBIO CRESCENT BIOPHARMA INC | Healthcare | 130.5K | $2.4M | 0.3% | New |
| MNPR MONOPAR THERAPEUTICS INC | Healthcare | 43.5K | $2.4M | 0.3% | New |
| OVID OVID THERAPEUTICS INC | Healthcare | 1.0M | $2.2M | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 73 | $979.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 12, 2026 | 68 | $720.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 82 | $741.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 65 | $542.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 69 | $489.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 61 | $457.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 71 | $445.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 70 | $423.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 77 | $360.1M | canonical | SEC ↗ |